Beyond TROP2 Expression: AI-Based Biomarker May Predict Datopotamab Deruxtecan Benefit in Lung Cancer

Coverage, in order

1. 7h ago
   
   OncoDaily obscure peer-reviewed

   Beyond TROP2 Expression: AI-Based Biomarker May Predict Datopotamab Deruxtecan Benefit in Lung Cancer

   An artificial intelligence-assisted analysis of tumor pathology has identified a potential predictive biomarker for datopotamab deruxtecan in advanced non-small-cell lung cancer. Published in Nature Medicine, the study demonstrates that the

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.